path

Melodious simran by Bhai Harjinder Singh Sri Nagar Wale.

Simran - Bhai Harjinder Singh

SALOK MAHALLA 9

Waheguru simran | GurMantar | WaheGuru Simran

Listen to 1 Hour Version: https://youtu.be/w0f5icFtXpk

WaheGuru Wahe Guru Satnam Waheguru Simran || Soothing Chanting Meditation Music

Copyright © 2022 Meditative Mind®

⌘ TRACK INFO ⌘
Track: WaheGuru Wahe Guru Satnam Waheguru
ISRC: AUTMZ2081135
SKU: w0f5icFtXpk
Music: Dilpreet Bhatia

WaheGuru Wahe Guru Satnam Waheguru

Listen 1Hour Version ▶

WaheGuru Wahe Guru Satnam Waheguru Simran || Soothing Chanting Meditation Music

STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. 

This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. 

Part 1 covers the landscape of prostate cancer treatment before STAMPEDE, as well how the trial was designed, featuring two researchers who lead the methodological and clinical sides of the trial: Max Parmar, Professor of Medical Statistics and Epidemiology and Director of the MRC Clinical Trials Unit at UCL and UCL's Institute of Clinical Trials and Methodology, and Nick James, Professor of Prostate and Bladder Cancer Research at the Institute of Cancer Research.

-

Further information is available on the STAMPEDE study page at www.mrcctu.ucl.ac.uk

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

For more information and to access the transcript: https://bit.ly/3OQWhV8

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

STAMPEDE (part 1): A new era for prostate cancer research with Max Parmar & Nick James

STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. 

This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. 

Part 2 is about patient and public involvement (PPI) in the trial. David Matheson, a Reader at the University of Wolverhampton and STAMPEDE patient representative, shares his insight into the work this entails and why it is so important to champion the voices of patients. We also hear about PPI from the perspective of trial researchers, Max Parmar and Nick James.

-
Further information is available on the STAMPEDE study page at www.mrcctu.ucl.ac.uk

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

For more information and to access the transcript: bit.ly/3OQWhV8

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

STAMPEDE (part 2): The role of the patient voice with David Matheson, Max Parmar & Nick James

www.RajKaregaKhalsa.Net

Anand Sahib

STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. 

This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. 

In the final part, Max Parmar and Nick James look back over the trial’s impact on clinical practice and platform trial design and look forward to STAMPEDE2, sharing their hopes for the future of prostate cancer research. 

-

Further information is available on the STAMPEDE study page at www.mrcctu.ucl.ac.uk

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

For more information and to access the transcript: bit.ly/3OQWhV8

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

STAMPEDE (part 3): Impact and legacy with Max Parmar & Nick James

Listen in Full Hi-Res Lossless Quality here: https://kirtanfi.com/43

#43 - Mahan Barsi Smagam 2022

BONUS - Waheguru Simran Loop - Bhai Jagpal Singh Ji (Kanpuri)

Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC CTU at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.  

The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS.  

Part 1 covers the treatment and research landscape of MS and the challenges of treating progressive MS. It features Jeremy Chataway, neurologist at the National Hospital for Neurology and Neurosurgery at UCLH, Professor of Neurology at UCL and co-lead of the Neurodegenerative Diseases progamme at the MRC CTU at UCL, who is leading the Octopus trial. We also hear from Dawn Lyle, Lead Research MS Nurse, and Matthew Justin, MS Specialist, who are based at the Anne Rowling Regenerative Neurologic Clinic in Edinburgh.  
-
For more information and to access the transcript: https://bit.ly/3S6FKP4

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Octopus (part 1): The MS landscape with Jeremy Chataway, Dawn Lyle and Matthew Justin

Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.  

The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS. 

Part 2 of the series explores our Octopus trial in depth. Professor Jeremy Chataway, lead investigator of Octopus, discusses its novel design, the treatments it will test, and the criteria for people to take part. He also explains the data researchers will collect and analyse to find out if a treatment is working.
-
For more information and to access the transcript: bit.ly/3S6FKP4 

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk 

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Octopus (part 2): Introducing the trial with Jeremy Chataway

Full Track: https://on.soundcloud.com/Jv9foshdHnoGnNmH9

Anand Sahib

SikhMum

Related tracks